Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 15/20 | 0.66 |
| ▸ | CPB1 | P15086 | 6/20 | 0.66 |
| ▸ | TRHR | P34981 | 1/20 | 0.37 |
| ▸ | TRHDE | Q9UKU6 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | CPA1 | P15085 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20419007 | 0.89 | CPB2 (0.53) | CPB2CPB1TRHRTRHDE | |
| SCHEMBL20441244 | 0.86 | CPB2 (0.50) | CPB2CPB1TRHRTRHDE | |
| SCHEMBL25431018 | 0.85 | CPB2 (0.46) | CPB2CPB1TRHR | |
| SCHEMBL3336369 | 0.85 | CPB2 (0.46) | CPB2CPB1TRHR | |
| SCHEMBL6268747 | 0.80 | CPB2 (1.00) | CPB2CPB1TRHDEKDM5AKDM5B | |
| SCHEMBL3839535 | 0.80 | CPB2 (1.00) | CPB2CPB1TRHDEKDM5AKDM5B | |
| SCHEMBL6328167 | 0.79 | CPB2 (0.64) | CPB2CPB1KDM5AKDM5B | |
| SCHEMBL10583023 | 0.79 | CPB2 (0.64) | CPB2CPB1KDM5AKDM5B | |
| SCHEMBL6329225 | 0.79 | CPB2 (0.64) | CPB2CPB1ACE | |
| SCHEMBL10137873 | 0.78 | CPB2 (0.64) | CPB2CPB1KDM5AKDM5BCPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018140580-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | 2C TECH CORP. (US) | 2018-08-02 | — | — | WO | disclosed |